openPR Logo
Press release

Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Phar

09-03-2025 08:46 PM CET | Associations & Organizations

Press release from: ABNewswire

Prostate Cancer Pipeline Analysis

Prostate Cancer Pipeline Analysis

DelveInsight's, "Prostate Cancer - Pipeline Insight, 2025," report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Prostate Cancer pipeline companies are Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, Cellbion Co., Ltd., and others.

According to DelveInsight, over 140 companies are actively developing more than 150 therapies for Prostate Cancer.

Prostate Cancer Overview:

Prostate cancer occurs when cells in the prostate gland start growing uncontrollably. The disease is primarily driven by DNA mutations that trigger abnormal cell growth. Prostate cancer is often diagnosed at a later stage, once symptoms appear, but early detection is possible through screening tests before symptoms develop.

Download our report @ https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

"Prostate Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Prostate Cancer Therapeutics Market.

Key Takeaways from the Prostate Cancer Pipeline Report

DelveInsight's Prostate Cancer pipeline report highlights a dynamic landscape with over 140 companies actively developing more than 150 therapies for prostate cancer.

Notable recent developments include:

*
February 2025: BioXcel Therapeutics announced FDA Fast Track designation for BXCL701 with a checkpoint inhibitor to treat metastatic small cell neuroendocrine prostate cancer (SCNC) in patients progressing on chemotherapy.

*
September 2024: Ipsen reported that the Phase III CONTACT-02 trial of Cabometyx Registered plus atezolizumab in metastatic castration-resistant prostate cancer (mCRPC) met progression-free survival (PFS) endpoints, though overall survival improvement was non-significant.

*
September 2024: Foundation Medicine received FDA approval for FoundationOne Registered CDx and Liquid CDx as companion diagnostics for Lynparza Registered in BRCA-mutated mCRPC.

*
July 2024: The ARANOTE trial showed that NUBEQA Registered plus androgen deprivation therapy (ADT) significantly improved radiological PFS in metastatic hormone-sensitive prostate cancer (mHSPC). FDA also granted Fast Track designation to SYNC-T SV-102 for mCRPC.

*
June 2024: Kangpu Biopharmaceuticals initiated a Phase II/III trial of KPG-121 with abiraterone in mCRPC.

*
May 2024: Fusion Pharmaceuticals launched the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC.

*
April 2024: Astellas Pharma obtained European approval for XTANDI Trademark in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC). FibroGen also reported positive Phase 1 results for FG-3246 in mCRPC.

Key players advancing the prostate cancer treatment landscape include Pfizer, Janssen, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas, Regeneron, Silenseed, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck, Amgen, BioNTech, Qilu Pharmaceuticals, and many others. Promising pipeline candidates include Niraparib, ZEN 3694, Ladiratuzumab, FOR46, REGN5678, and more.

Prostate Cancer Pipeline Analysis

The Prostate Cancer pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Prostate Cancer Market.

*
Categorizes Prostate Cancer therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Prostate Cancer drugs under development based on:

*
Stage of development

*
Prostate Cancer Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Prostate Cancer Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Prostate Cancer Licensing agreements

*
Funding and investment activities supporting future Prostate Cancer market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Prostate Cancer Emerging Drugs

*
Niraparib: Janssen Research & Development

*
ZEN 3694: Zenith Epigenetics

*
Ladiratuzumab vedotin: Seagen

*
FOR46: Fortis Therapeutics

*
REGN5678: Regeneron Pharmaceuticals

Prostate Cancer Companies

More than 140 companies are developing therapies for prostate cancer, with Janssen Research & Development leading the field with candidates in the advanced Phase III stage.

DelveInsight's report covers around 150+ products under different phases of Prostate Cancer clinical trials like

*
Prostate Cancer Late stage Therapies (Phase III)

*
Prostate Cancer Mid-stage Therapies (Phase II)

*
Prostate Cancer Early-stage Therapies (Phase I)

*
Prostate Cancer Pre-clinical and Prostate Cancer Discovery stage Therapies

*
Prostate Cancer Discontinued & Inactive Therapies

Prostate Cancer pipeline report provides the Prostate Cancer therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Prostate Cancer Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Prostate Cancer Therapies and Key Prostate Cancer Companies: Prostate Cancer Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Prostate Cancer Pipeline Therapeutic Assessment

- Prostate Cancer Assessment by Product Type

- Prostate Cancer By Stage

- Prostate Cancer Assessment by Route of Administration

- Prostate Cancer Assessment by Molecule Type

Download Prostate Cancer Sample report to know in detail about the Prostate Cancer treatment market @ Prostate Cancer Therapeutic Assessment [https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Prostate Cancer Current Treatment Patterns

4. Prostate Cancer - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Prostate Cancer Late-Stage Products (Phase-III)

7. Prostate Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Prostate Cancer Discontinued Products

13. Prostate Cancer Product Profiles

14. Prostate Cancer Key Companies

15. Prostate Cancer Key Products

16. Dormant and Discontinued Products

17. Prostate Cancer Unmet Needs

18. Prostate Cancer Future Perspectives

19. Prostate Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Prostate Cancer Pipeline Reports Offerings [https://www.delveinsight.com/report-store/prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=prostate-cancer-pipeline-analysi-2025-by-delveinsight-pfizer-janssen-pharmaceutical-point-biopharma-tavanta-therapeutics-exelixis-astellas-pharma-inc-antev-orca-therapeutics-regeneron-phar]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Phar here

News-ID: 4168820 • Views:

More Releases from ABNewswire

ALK NSCLC Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
ALK NSCLC Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approval …
DelveInsight's, "ALK+ NSCLC Pipeline Insight 2025" report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK+ NSCLC pipeline landscape. It covers the ALK+ NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ALK+ NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment
Amyotrophic Lateral Sclerosis Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
Amyotrophic Lateral Sclerosis Pipeline Outlook 2025: Clinical Trial Studies, EMA …
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Amyotrophic
NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Ap …
DelveInsight's, "NK Cell Therapies Pipeline Insight, 2025" report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the NK Cell Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapies pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the
RNA Interference Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
RNA Interference Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA A …
DelveInsight's, "RNA Interference Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers the RNA Interference therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment

All 5 Releases


More Releases for Prostate

04-14-2025 | Health & Medicine
Getnews
The 3D Urology and Prostate Clinics Introduces Innovative Natural and Targeted P …
The 3D Urology and Prostate Clinics introduces its innovative 3D targeted injection therapies, offering effective, natural solutions for various prostate conditions including prostatitis, enlarged prostate, and prostate cancer. Renowned for its pioneering approach to prostate health, The 3D Urology and Prostate Clinics is bringing renewed hope to patients worldwide suffering from various prostate diseases. Utilizing advanced diagnostic techniques and a unique targeted injection method, the clinics offer specialized treatments that focus
12-10-2024 | Health & Medicine
Getnews
The 3D Urology and Prostate Clinics Introduces Advanced 3D Prostate Targeted Tre …
The 3D Urology and Prostate Clinics announces its latest breakthrough in targeted prostate treatment, offering a revolutionary approach to prostate cancer and other prostate-related conditions. The 3D Urology and Prostate Clinics, renowned for its advanced techniques in prostate health, is proud to present its groundbreaking 3D prostate Targeted Treatment, a comprehensive and non-invasive solution for men suffering from prostate conditions. The clinic's innovative treatment is designed to target the root causes
11-29-2024 | Health & Medicine
Getnews
The 3D Urology and Prostate Clinics Unveil Innovative 3D Prostate Targeted Treat …
The 3D Urology and Prostate Clinics introduce their groundbreaking 3D prostate targeted treatment, offering a non-invasive solution for prostate health issues. The 3D Urology and Prostate Clinics, renowned for their specialized treatments in prostate health, are proud to unveil their innovative 3D prostate targeted treatment. This cutting-edge therapy provides a non-invasive, highly effective solution for prostate-related conditions, offering patients a new path to recovery and well-being.Image: https://i.imgur.com/NCfbb6S.jpg At the heart of this
07-29-2024 | Health & Medicine
Getnews
The 3D Urology and Prostate Clinics Unveils Advanced 3D prostate Targeted Treatm …
The 3D Urology and Prostate Clinics is at the forefront of prostate care, offering the advanced 3D Targeted Therapy as a precise and effective treatment solution. The 3D Urology and Prostate Clinics is proud to announce its revolutionary 3D prostate Targeted Treatment [http://www.3dprostatecure.com/page.php?cata_id=19], setting a new standard in prostate care. This highly advanced treatment option utilizes cutting-edge technology to deliver focused treatment, minimizing side effects and enhancing recovery for patients. Men
3D Prostate Cure: Revolutionizing Prostate Treatment with Targeted Therapy
This news release highlights the 3D Urology and Prostate Clinics' innovative approach to prostate treatment using 3D Targeted Therapy, offering a safe and effective alternative to traditional methods. As a global leader in men's health, The 3D Urology and Prostate Clinics is committed to providing cutting-edge treatments for various prostate conditions. The clinic is proud to announce its revolutionary 3D Targeted Therapy, offering a new standard in prostate care. This innovative therapy
06-22-2024 | Health & Medicine
Getnews
The 3D Urology and Prostate Clinics Enhance Prostate Health with Advanced 3D Pro …
The 3D Urology and Prostate Clinics are revolutionizing prostate care with their comprehensive treatments, including the 3D prostate Targeted Treatment and 3D Targeted Therapy, developed to ensure effective, non-surgical solutions for prostate health issues. At the forefront of prostate health, The 3D Urology and Prostate Clinics are excited to offer innovative treatments such as the 3D prostate Targeted Treatment and 3D Targeted Therapy. These treatments are part of the clinic's commitment